4,5-dichlorobenzene-1,3-disulfonamide

• ChemBase编号: 1015
• 分子式: C6H6Cl2N2O4S2
• 平均质量: 305.15884
• 单一同位素质量: 303.91460404
• SMILES: Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N)cc1Cl
• Canonical SMILES: Clc1cc(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)N
• InChI: InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)
• InChIKey: GJQPMPFPNINLKP-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4,5-dichlorobenzene-1,3-disulfonamide
• IUPAC传统名: dichlorphenamide
• 商标名: Antidrasi; Daranide; Dasanide; Glaucol; Oratrol
• 别名: Diclofenamida [INN-Spanish]; Diclofenamide; Diclofenamidum [INN-Latin]; Dichlorphenamid; Dichlorophenamide; Dichlofenamide; Dichlorphenamide; 1,3-Disulfamoyl-4,5-dichlorobenzene; 1,3-Disulfamyl-4,5-dichlorobenzene; 3,4-Dichloro-5-sulfamylbenzenesulfonamide; 4,5-Dichloro-1,3-disulfamoylbenzene; 4,5-Dichloro-m-benzenedisulfonamide; Antidrasi; CB 8000; Daramide; Daranide; Dichlorphenamide; Diclofenamid; Glaucol; Oratrol; Diclofenamide; 4,5-DICHLOROBENZENE-1,3-DISULFONAMIDE

登记号

• CAS号: 120-97-8
• PubChem SID: 46505039; 160964478
• PubChem CID: 3038

理论计算性质

JChem

• Acid pKa: 8.442037
• 质子受体: 4
• 质子供体: 2
• LogD (pH = 5.5): 0.3929572
• LogD (pH = 7.4): 0.35977012
• Log P: 0.3933967
• 摩尔折射率: 59.9834 cm^3
• 极化性: 25.071486 Å^3
• 极化表面积: 120.32 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.92
• LOG S: -2.88
• 溶解度: 3.98e-01 g/l

分子性质

理化性质

• 溶解度: Chloroform; Methanol
• 外观: Off-White Solid
• 熔点: 237-240°C
• 疏水性(logP): 0.2

安全信息

• 保存条件: -20°C; Refrigerator

详细说明

DrugBank - DB01144

• Drug Groups: approved
• Description: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. [PubChem]
• Indication: For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure
• Pharmacology: Dichlorphenamide is an oral carbonic anhydrase inhibitor indicated for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow).
• Affected Organisms: Humans and other mammals
• Protein Binding: 55%
• References: Tawil R, McDermott MP, Brown R Jr, Shapiro BC, Ptacek LJ, McManis PG, Dalakas MC, Spector SA, Mendell JR, Hahn AF, Griggs RC: Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol. 2000 Jan;47(1):46-53. [Pubmed] ; Okada S, Izumi W, Murai M, Komatsu H, Ishimitsu S: [Diclofenamide Reference Standard (Control 891) of National Institute of Hygienic Sciences] Eisei Shikenjo Hokoku. 1991;(109):148-50. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

DrugBank - DB07948

Drug information: experimental

Selleck Chemicals - S2177

Research Area: Neurological Disease
Biological Activity:
Diclofenamide (Dichlorphenamide) is a sulfonamide and a carbonic anhydrase inhibitor of the meta-Disulfamoylbenzene class. It is used as an adjunct to reduce intraocular pressure in the treatment of glaucoma. [1]

Toronto Research Chemicals - D436530

Diclofenamide is a potent carbonic anhydrase inhibitor. Diclofenamide may provide a therapeutic strategy in the inhibition of the human cytosolic isoforms I and II and transmembrane tumor-associated isoenzymes IX and XII. Diclofenamide has been shown to b

参考文献

• Tawil R, McDermott MP, Brown R Jr, Shapiro BC, Ptacek LJ, McManis PG, Dalakas MC, Spector SA, Mendell JR, Hahn AF, Griggs RC: Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol. 2000 Jan;47(1):46-53. Pubmed
• Okada S, Izumi W, Murai M, Komatsu H, Ishimitsu S: [Diclofenamide Reference Standard (Control 891) of National Institute of Hygienic Sciences] Eisei Shikenjo Hokoku. 1991;(109):148-50. Pubmed
• http://en.wikipedia.org/wiki/Dichlorphenamide
• Brzozowski, Z. et al.: Eur. J. Med. Chem., 46, 3656 (2010)
• Tawil, R. et al.: Ann. Neurol., 47, 46 (2010)
• Casey, J. et al.: J. Med. Chem., 47, 2337 (2010)